Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Lm-LLO-TT

Phase 1

LLoki Therapeutics, Inc.

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[2][1]

Indication

Pancreas Cancer, Duct Cell AdenocarcinomaNot yet recruiting

Pancreas Cancer, Duct Cell AdenocarcinomaPhase 1

Not yet recruiting

Timeline

Expected Milestones

Q1 2029

Phase 1Not yet recruiting

Pancreas Cancer, Duct Cell Adenocarcinoma

NCT07828236

Clinical

Trials by Indication[1]

Pancreas Cancer, Duct Cell Adenocarcinoma1 trial

PHASE 1, OPEN-LABEL, FIRST-IN-HUMAN TRIAL OF INTRAPERITONEA L Lm-LLO-TT AND GEMCITABINE IN PARTICIPANTS WITH UNRESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA

Not yet recruiting·LLoki Therapeutics, Inc.·Phase 1·NCT07828236·18 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Lm-LLO-TT. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Lm-LLO-TT. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Loki Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: LLoki Therapeutics, Inc.

Related News